.-In the brains of teleosts, angiotensin II (ANG II), one of the main effector peptides of the renin-angiotensin system, is implicated in various physiological functions notably body fluid and electrolyte homeostasis and cardiovascular regulation, but nothing is known regarding the potential action of ANG II and other angiotensin derivatives on ventilation. Consequently, the goal of the present study was to determine possible ventilatory and cardiovascular effects of intracerebroventricular injection of picomole doses (5-100 pmol) of ]-ANG II were detected (ca. 40 fmol/mg brain tissue), but ANG III was not detected, and the amount of ANG IV was about eightfold lower than the content of the ANG IIs. In plasma, ANG IIs were also the major angiotensins (ca. 110 fmol/ml plasma), while significant but lower amounts of ANG III and ANG IV were present in plasma. In conclusion, our study suggests that the two ANG II isoforms produced within the brain may act as a neurotransmitter and/or neuromodulator to regulate the cardioventilatory functions in trout. In the periphery, two ANG IIs and their COOH-terminal peptides may act as a circulating hormone preferentially involved in cardiovascular regulations. ventilatory control; heart rate and blood pressure; intracerebroventricular injection; teleost RECENT EVIDENCE recognized that all components of the reninangiotensin system (RAS) are present within the brain of mammals and that the production of bioactive peptides is similar to that of the circulating RAS. After enzymatic cleavage from the glycoprotein precursor angiotensinogen by renin, the decapeptide angiotensin I (ANG I) is converted to the octapeptide angiotensin II (ANG II) by the angiotensin-converting enzyme (ACE) or by other enzymatic pathways. Subsequently, ANG II is metabolized to ANG III [ANG II (2-8)] by the aminopeptidase A, and ANG III is further converted to ANG IV [ANG II (3-8)] by action of the aminopeptidase N. In addition, a COOH terminally truncated ANG II, ANG 1-7 can be generated by ACE-independent pathways from ANG I or after the action of the ACE 2 (10, 35). Recently, a novel angiotensinogen-derived peptide angiotensin 1-12 (ANG 1-12) (initially known as proangiotensin 12) has been purified and sequenced from the rat small intestine. Tissue distribution revealed that ANG 1-12 was abundantly present in the rat brain (27). ANG 1-12 can be processed to ANG II (27). ANG II and ANG III bind to angiotensin receptor type 1 (AT 1 ) and type 2 (AT 2 ). ANG IV binds exclusively to angiotensin receptor type 4 (AT 4 ). The type of receptor that mediates the actions of ANG 1-7 is somewhat controversial. Considerable amounts of data have demonstrated that, in addition to the two main effector peptides of the brain RAS, ANG II and ANG III, ANG IV, and to a lesser extend ANG 1-7 are implicated in various physiological functions notably body fluid homeostasis and blood pressure regulation but also pituitary hormone release, thermoregulation, sexual, eating and locomotor behaviors, metabolism, learning, and memory (28, 29, 35, 36, 42, 54) . Compared with the central actions of the RAS on cardiovascular regulations, studies on the ventilatory effect are sparse and only the action of ANG II has been explored with conflicting results in mammals (13, 31, 33, 37, 41, 50) .
of the circulating RAS. After enzymatic cleavage from the glycoprotein precursor angiotensinogen by renin, the decapeptide angiotensin I (ANG I) is converted to the octapeptide angiotensin II (ANG II) by the angiotensin-converting enzyme (ACE) or by other enzymatic pathways. Subsequently, ANG II is metabolized to ANG III [ANG II (2) (3) (4) (5) (6) (7) (8) ] by the aminopeptidase A, and ANG III is further converted to ANG IV [ANG II (3) (4) (5) (6) (7) (8) ] by action of the aminopeptidase N. In addition, a COOH terminally truncated ANG II, ANG 1-7 can be generated by ACE-independent pathways from ANG I or after the action of the ACE 2 (10, 35) . Recently, a novel angiotensinogen-derived peptide angiotensin 1-12 (ANG 1-12) (initially known as proangiotensin 12) has been purified and sequenced from the rat small intestine. Tissue distribution revealed that ANG 1-12 was abundantly present in the rat brain (27) . ANG 1-12 can be processed to ANG II (27) . ANG II and ANG III bind to angiotensin receptor type 1 (AT 1 ) and type 2 (AT 2 ). ANG IV binds exclusively to angiotensin receptor type 4 (AT 4 ). The type of receptor that mediates the actions of ANG 1-7 is somewhat controversial. Considerable amounts of data have demonstrated that, in addition to the two main effector peptides of the brain RAS, ANG II and ANG III, ANG IV, and to a lesser extend ANG 1-7 are implicated in various physiological functions notably body fluid homeostasis and blood pressure regulation but also pituitary hormone release, thermoregulation, sexual, eating and locomotor behaviors, metabolism, learning, and memory (28, 29, 35, 36, 42, 54) . Compared with the central actions of the RAS on cardiovascular regulations, studies on the ventilatory effect are sparse and only the action of ANG II has been explored with conflicting results in mammals (13, 31, 33, 37, 41, 50) .
The RAS has an ancient evolutionary history and most of its components are present in lampreys, elasmobranchs, and teleosts (29, 32, 38, 46, 53) . In contrast to the well-known peripheral cardiovascular and osmoregulatory effects of ANG II (5, 32, 45) , studies on the central action are sparse in fishes. ]-ANG II into the third or fourth ventricle is known to induce drinking (15) , to increase heart rate (HR) and blood pressure (30) in the eel Anguilla japonica, and also to elevate HR and blood pressure but to reduce both HR variability and the cardiac baroreflex sensitivity in the trout Oncorhynchus mykiss (16, 18) . In addition, local injection of [Asn 1 ]-ANG II within the dorsal vagal motor nucleus of the trout potently enhances HR but only weakly increases blood pressure (34) . Taken together, these results demonstrate that in the brains of teleosts as in the mammalian brain, ANG II may act as a neuromodulator or a neurotransmitter involved in key osmoregulatory and cardiovascular regulations. Nonetheless, no information is available about the possible central action of ANG II peptides on the central command of ventilation in teleosts, a vital physiological function that allows proper respiratory efficiency in aquatic environment subjected to large oxygen availability. The unanesthetized trout has been proven to be an interesting model to study the regulatory actions of various neuropeptides on ventilation (17, 20 -23 (16, 18, 24, 26, 30, 34) . The central effects of these peptides were also compared with their peripheral effects. Finally, we determined the angiotensin peptides produced in the brain and circulating in plasma of trout using the high-performance liquid chromatography (HPLC) system that can separate these peptides. (9) and trout ANG III were obtained from Sigma Chemical (Saint-Quentin Fallavier, France). ANG IV and ANG 1-7 were purchased from Peptide Institute (Osaka, Japan). The primary structure of the synthetic angiotensin peptides examined is shown on Table 1 . The peptides were stored in stock solution at Ϫ25°C. Immediately before use, the peptides were diluted to the desired concentration with Ringer solution (vehicle). The composition of the Ringer solution was (in mM) 124 NaCl, 3 KCl, 0.75 CaCl 2, 1.30 MgSO4, 1.24 KH2PO4, 12 NaHCO3, and 10 glucose (pH: 7.8). All solutions were sterilized by filtration through 0.22-m filters (Millipore, Molsheim, France) before injection.
MATERIALS AND METHODS

Peptides.
Animals. The in vivo experiments on trout were performed in the Laboratory of Neurophysiology in Brest (France). Adult rainbow trout Oncorhynchus mykiss (263 Ϯ 1.7 g body wt, means Ϯ SE, N ϭ 151) of both sexes were purchased locally and transferred in a welloxygenated and thermostatically controlled water tank to the laboratory. All the fish were kept in a 1,000-liter tank containing circulating dechlorinated, aerated tap water (11-12°C), under a standard photoperiod (lights on 09:00 -20:00 h). The fish were allowed at least 3 wk to acclimate under these conditions before the experiments were started. Experimental protocols were approved by the Regional Ethics Committee in Animal Experiments of Rennes, France.
Experimental procedures. All surgical procedures were made under tricaine methane sulfonate (3-amino-benzoic acid ethyl ester; 60 mg/l in tap water buffered with NaHCO 3 to pH ϭ 7.3-7.5) anesthesia. The techniques used for placement of the electrocardiographic (ECG) electrodes, placement of the buccal catheter, cannulation of the dorsal aorta, and insertion of the intracerebroventricular (ICV) microguide have previously been described in detail (17, 25) . Briefly, two ECG AgCl electrodes (Comepa, 93541 Bagnolet, France) were subcutaneously implanted ventrally and longitudinally at the level of the pectoral fins. The incision was sutured across the electrodes, and the leads were sutured to the skin. The dorsal aorta was cannulated with a PE-50 catheter (44) . A flared cannula (PE-160) was inserted into a hole drilled between the nares such that its flared end was resting against the roof of the mouth. This cannula was used to record any changes in buccal ventilatory pressure (12) . The absence of a neocortex in fish allowed the accurate placement of the ICV microguide under stereomicroscopic guidance. A 25-gauge needle fitted with a PE-10 polyethylene catheter was inserted between the two habenular ganglia and descended into the third ventricle until its tip lay between the two preoptic nuclei (20) . An obturator was placed at the end of the PE-10 tubing, and the cranial surface was covered with hemostatic tissue followed by light quick-curing resin. After surgery, the animals were force ventilated with dechlorinated tap water and, following recovery of opercular movements, were transferred to a 6-liter blackened chamber supplied with dechlorinated and aerated tap water (10 -11°C) that was both recirculating and through flowing. Oxygen pressure within the water tank (PwO 2) and pH were continuously recorded and maintained at constant levels (PwO 2 ϭ 20 kPa; pH ϭ 7.4 -7.6). A small horizontal aperture was made along the upper edge of the chamber to connect the ECG leads to an amplifier and to connect the dorsal aorta and the buccal cannula to pressure transducers. This aperture permitted ICV and intra-arterial (IA) injections of peptides without disturbing the trout.
The trout were allowed to recover from surgery and to become accustomed to their new environment for 48 -72 h. Each day, the general condition of the animals was assessed by observing their behavior, checking the ventilatory and the cardiovascular variables, and measuring their hematocrit. Animals that did not appear healthy, according to the range of values detailed in our previous studies, were discarded. After stable ventilatory frequency (VF), ventilatory amplitude (VA), mean dorsal aortic blood pressure (PDA), and HR were maintained for at least 90 min, parameters were recorded for 30 min without any manipulation, ICV, or IA injection in control experiments.
Intracerebroventricular administration of the angiotensin peptides. The injector was introduced within the ICV guide before the beginning of a recording session which lasted 30 min. All injections were made at the fifth minute of the test, but the injector was left in place for a further 5 min to allow for complete diffusion of the agent and to minimize the spread of substances upwards in the cannula tract.
The fish first received an ICV injection of vehicle (0. (25, 50 , and 100 pmol in 0.5 l), ANG IV and ANG 1-7 (50 and 100 pmol in 0.5 l). Previous control experiments using two ICV injections 30 min apart have shown the absence of time-dependent changes in the measured variables using this protocol (20) . The animals received no more than two ICV injections of peptide per day with a delay of at least 5 h between the injections. The peptides were given in random order within and between fish. No single fish was studied for more than 2 days, and control experiments revealed that there was no significant change in performance over this period.
Intra-arterial administration of the angiotensin peptides. ]-ANG II, and ANG III were tested at doses of 5, 25, and 50 pmol. ANG IV and ANG 1-7 were tested at doses of 50 and 100 pmol. Peptides were administered in random order.
Plasma and brain tissue collections. Six trout were rapidly caught (Ͻ10 s) and anesthetized as previously stated. After puncture of the dorsal aorta, about 1 ml of blood was collected in Eppendorf tube containing 30 l of inhibitor solution (5.5 mM 1.10-phenanthronline, 0.75 M EDTA, and 2 TIU aprotinin) and immediately centrifuged at 4°C. The plasma was stored frozen at Ϫ80°C. The trout were decapitated and the whole brain was removed and stored in preweight vials. The brain was then immediately frozen in liquid nitrogen and stored at Ϫ80°C. Plasma and brain angiotensins extraction. Half milliliter of 1 M HCl-water-acetone (40:5:1) was added to half milliliter frozen plasma and rigorously vortexed. The large protein was precipitated by incubation of the mixture at Ϫ20°C for 30 min. After centrifugation at 10,000 g for 15 min at 4°C, the supernatant was frozen at Ϫ80°C and then lyophilized overnight.
After being weighed, the frozen brain was thawed in 1 M acetic acid (wt:vol, 1:4), and the content was boiled at 100°C for 10 min. The tissue was then homogenized in a polytron at room temperature. Crude brain homogenate was added an equal volume of acidic acetone (see Plasma and brain angiotensins extraction). The extraction procedure was then similar to that described for plasma sample (see Plasma and brain angiotensins extraction). Lyophilized samples were shipped to the Ocean Research Institute, University of Tokyo for the identification and determination of the concentration of the angiotensin peptides.
Identification of angiotensin subtypes. The ANG II peptides were identified according to Wong and Takei (52) . Briefly, freeze-dried plasma samples were reconstituted in 10% acetonitrile with 10 mM ammonium acetate, pH 7.0, and they were resolved by a reverse-phase HPLC system (Tosoh PU-980, Tokyo) attached to a UV-absorbance detector (Tosoh, UV-970, Tokyo) and utilizing an analytical column (Tosoh, ODS 100S column, Tokyo). A linear gradient from 15 to 35% acetonitrile in 10 mM ammonium acetate, pH 7.0, over 40 min was used for the separation. The column was maintained at 50°C and flow rate was adjusted to 1 ml/min. This protocol is optimized for the separation of 
Data acquisition and analysis of the ventilatory and the cardiovascular variables.
The ECG electrodes were connected to a differential amplifier (band pass: 5-50 Hz; Bioelectric amplifier, Gould & Nicolet, 91942 Courtaboeuf, France), and a stainless steel bar was immersed in the water of the tank to act as a reference electrode. The aortic cannula and the buccal catheter were connected to P23XL pressure transducers (band-pass: 0 -15 Hz; Gould & Nicolet). These pressure transducers were calibrated each day using a static water column. At the beginning of the experiments, the zero-buccal pressure level was set electronically. The output signals from the devices were digitalized at 1,000 Hz and visualized on the screen of a PC using PowerLab 4/30 data acquisition system (ADInstruments, Oxford, UK) and LabChart Pro software (v.6.0; ADInstruments) during the 30-min recording period and the data were stored on a disc. The time series related to the ventilatory, the pulsatile PDA, and the ECG signals were then processed off-line with custom-made programs written in LabView 6.1 (Laboratory Virtual Instrument Engineering Workbench, National Instruments, Austin, TX). The ventilatory and cardiovascular variables were calculated as previously described (17, 21) . Segments free of any movement artifacts on the ventilatory signal were selected, and VF (breaths/min) and VA (arbitrary units, a.u.) were determined. VA was calculated from the difference between the maximal abduction phase and the maximal adduction phase for each of the ventilatory movements. The net effect of the changes in VF and VA on ventilation was estimated according to the formula VTOT ϭ VF ϫ VA, where VTOT (in a.u.) is total ventilation. The mean PDA (in kPa) was calculated from the pulsatile PDA as the arithmetic mean between the systolic blood pressure and the diastolic blood pressure ,and the mean HR (in beats/min) was determined from the ECG signal. All calculations for VF, VA, V TOT, PDA, and HR were made for the preinjection period (0 -5 min) and for five postinjection periods of 5 min for each trout, and the results were averaged for trout subjected to the same protocol.
Statistical analysis. Data are expressed as means Ϯ SE or means ϩ SE for each 5-min period. In the figures, table, and text, data refer to absolute values or maximal changes from baseline (preinjection) values and as percentage changes. For the time-course studies, the data were analyzed initially using two-way ANOVA (treatments and time) followed by the Bonferroni post hoc test for comparisons between groups. Within each group of trout receiving peptide, when the overall preceding two-way ANOVA analysis demonstrated statistically significant differences compared with vehicle-injected trout, Dunnett's test was used for comparisons of postinjection values with preinjection values. The criterion for statistical difference between groups was P Ͻ 0.05. The statistical tests were performed using GraphPad Prism 5.0 (GraphPad, San Diego, CA). (Fig. 2B) . Consequently, the net effect of the peptide was a hyperventilatory response involving a significant elevation of V TOT (Fig. 2C) Fig. 2D ). In contrast, a sustained tachycardic action of the peptide was observed after ICV injection of [Asn 1 ]-ANG II (Fig. 2E) . The minimal effective dose for inducing a significant tachycardic effect was 5 pmol, and in this case the latency for (Fig. 3D) and tachycardic (Fig. 3E ]-ANG II on VA and V TOT , central injection of ANG III produced no significant action on any ventilatory variables (Fig. 4, A-C) . The lowest doses of ANG III (25 pmol) was without action on the cardiovascular variables (Fig. 4, D and  E) . The threshold dose of 50 pmol was required to observed a significant hypertensive and tachycardic actions of the peptide (P DA : ϩ0.24 Ϯ 0.09 kPa; HR: ϩ10.7 Ϯ 2.5 beats/min vs. preinjection, P Ͻ 0.05, Fig. 4, D and E) , and these effects were observed after a delay of only 5 min for the blood pressure increase but of 10 min for the elevation in HR. However, a twofold increase in this dose was required to obtain a maximum increase in HR (ϩ19.7 Ϯ 3.8 beats/min vs. preinjection, P Ͻ 0.05), a value not significantly different from that observed following the ICV injection of only 50 pmol of the ANG IIs. No further obvious increase in P DA can be detected following the highest dose of ANG III.
RESULTS
Ventilatory and cardiovascular responses to central [Asn
Ventilatory and cardiovascular responses to central ANG IV and ANG 1-7.
In contrast to the actions of the two ANG II subtypes on ventilation (Fig. 2 and Fig. 3, A-C) , the ICV injection ]-ANG II produces a marked increase of the ventilatory amplitude, a weak elevation of ventilatory frequency and pulsatile PDA, but a potent increase in heart rate.
of ANG IV and ANG 1-7 caused no change in the ventilatory variables even at the highest dose of 100 pmol (data not shown). This absence of effect of ANG IV and ANG 1-7 on ventilation is thus similar to that noted above for ANG III. However, the effects of ANG IV and ANG 1-7 differed from those of the two ANG II subtypes and ANG III due to their absence of effect on the cardiovascular variables (data not shown). (Table 2) . At a dose of 50 pmol, the maximal increases in P DA compared with preinjection value were respectively 80%, 58%, and 48% (P Ͻ 0.05 vs. preinjection values, Table 2 ). These increases in P DA were not statistically different among these angiotensin peptides. Although HR decreased following the IA injection of these angiotensin peptides, the changes in HR were not statistically significant compared with preinjection values. No significant change in the cardiovascular variables was observed following the IA injection of ANG IV and ANG 1-7 even at the highest dose of 100 pmol (data not shown).
Ventilatory and cardiovascular responses to peripheral [Asn
Brain tissue and plasma angiotensins content. ]-ANG II was the highest reaching quite similar value (about 110 fmol/ ml). The plasma concentration of ANG III and ANG IV were respectively 12-fold and 4-fold lower than the plasma concentration of the two ANG II subtypes.
DISCUSSION
The most important outcome of this study is that picomolar doses of angiotensin peptides elicited differential ventilatory ]-ANG II into the third ventricle elevates both P DA and HR (24, 30) . In the present study, we confirmed these results and further demonstrated that substitution in the first amino acid (Asn/Asp) increased the threshold dose by fivefold at which a significant tachycardic action can be observed following ICV injection (Fig. 2D and Fig. 3D ). In contrast, the hypertensive action of ANG II was not significantly affected by this substitution (Fig. 2E and Fig. 3E ). ANG III was still able to elevate HR and blood pressure but its potency was reduced compared with ANG IIs. Collectively, these results support the concept that cardiovascular and ventilatory actions of angiotensin peptides can be dissociated and might be related to the existence of two distinct functional receptors, one related to ventilatory regulation and the other to cardiovascular functions. It was previously proposed that in trout, [Asn 1 ]-ANG II is the product of the angiotensinogen cleavage in plasma but that this peptide is converted to [Asp 1 ]-ANG II by plasma asparaginase (9) . In the eel plasma, asparaginase activity is low and the conversion seems to occur in the tissues such as liver and kidney with angiotensinogen, not ANG II (52) . In the present study, the two ANG IIs were found in trout plasma and brain tissue suggesting that the conversion occurs not only in plasma but also in the brain. The failure to detect ANG III in the brain of the trout suggests that its brain level is very low compared with other angiotensins, or it is localized only in restricted brain nuclei.
Central actions of ANG IV and ANG [1] [2] [3] [4] [5] [6] [7] . Although this study demonstrated the presence of ANG IV in trout brain tissue, the absence of effect of ANG IV on cardioventilatory functions supports the view that the first two NH 2 -terminal amino acids of ANG II are essential for its full action on the ventilatory and cardiovascular variables. The COOH terminally truncated ANG 1-7 was also devoid of any cardiovascular and ventilatory action after central injection, confirming a key function of COOH-terminal Phe for expression of the full central cardioventilatory activity. However, our RIA does not allow the measurement of ANG 1-7 in brain extracts so that the endogenous production of this peptide remains to be elucidated. In the rat hypothalamus, equimolar amounts of ANG I, ANG II, and ANG 1-7 were detected but the concentration of these three peptides in the medulla oblongata was less than that seen in hypothalamus (7). ANG 1-7 has many actions within the brain of mammals mostly counteracting the effects of ANG II (35) . For instance, in rats, microinjection of ANG II and ANG 1-7 into the caudal ventrolateral medulla have opposing effects suggesting that the COOH-terminal residue dictates functional specificity of responses (2) . Therefore, it might be of special interest to determine whether centrally administered ANG 1-7 also affects ANG II-mediated reduction in the cardiac baroreflex sensitivity in trout (16) . To our knowledge, the ventilatory actions of ANG III, ANG IV, and ANG 1-7 in mammals have never been explored, and the actions of peripherally administered ANG II have proved conflicting (1, 31, 33, 37, 51) . In mammals, neuronal AT 1 receptor mediates ANG II effects on blood pressure, salt, and water intake (10), but nothing is known about the AT receptor(s) that mediate(s) the ventilatory action of ANG II. It has been proposed that the teleost AT receptor is an AT 1 -like receptor (39) . The demonstration that in our study both ANG IIs and ANG III elevate P DA and HR while the other angiotensins were without action supports the idea that AT 1 -like receptor might also be involved in the central cardiovascular actions of ANG IIs and ANG III. A novel receptor that binds specifically or with a higher affinity the ANG IIs but not the truncated ANG IIs might be concerned with the ventilatory effect of the brain RAS in trout.
We recently demonstrated that after third ventricle injection within the trout brain, calcitonin gene-related peptide ( Sites of actions of central angiotensins and possible physiological significance. The level at which ANG II peptides acts on the neural networks involved in the control of ventilation in trout cannot be established from the present experiment. However, it is reasonable to speculate that since they were injected into the third ventricle at the level of the nucleus preopticus, they might primarily affect the activity of the preoptic neurons that could project to critical brain stem respiratory nuclei. Neuroanatomical data favor this hypothesis. Some neuropeptidergic preoptic neurons colocalize arginine vasotocin (AVT) and ANG II (55) , and AVT and isotocin preoptic neurons project toward critical cardiovascular and respiratory brain stem nuclei including the nucleus tractus solitarius and the dorsal vagal motor nucleus (4, 40) . In addition, ANG II peptides may diffuse within the cerebrospinal fluid toward the fourth ventricle to control the activity of the periventricularly located cardiovascular and respiratory nuclei. In agreement with this hypothesis is the report that ANG II binding sites have been demonstrated in the medulla oblongata of the rainbow trout (8) . As in other vertebrates, the medulla oblongata is thought to be the site where the respiratory rhythm generator (RRG) resides in fish (43, 47) . The RRG receives afferent inputs from peripheral chemoreceptors and mechanoreceptors, which are mostly located within the orobranchial cavity (47) . The RRG controls the activity of trigeminal Vth, facial VIIth, glossopharyngeal IXth, vagal Xth, and motor nuclei, all of which drive the breathing muscles (47) . In addition, the RRG receives modulatory inputs from higher brain centers (47) , but the origin and the neurochemical nature of these neuronal inputs are unknown (11) . Studies in the shorthorn sculpin Myoxocephalus scorpius have shown that glutamatergic pathways within the medulla oblongata are essential for the control of ventilation and N-methyl-D-aspartate (NMDA) receptors mediate VF, while non-NMDA receptors are vital for the control of VA (48, 49) . We assume that ANG II peptides also act as neurotransmitters or neuromodulators to interact with the neuronal elements involved in the central command of ventilation.
In our study, the possible physiological significance of the observed effects of ANG IIs and ANG III is unkown. During hypoxia, a condition that is not associated with hypotension in trout, the RAS is activated and ANG II contributes to the release of catecholamines (19) . However, in trout under mod- All data are presented as means Ϯ SE; n ϭ number of fish. Results for the postinjection period are shown as maximal changes from the baseline (preinjection, 0 -5 min) level. PDA, mean dorsal aortic blood pressure; HR, heart rate. *P Ͻ 0.05 vs. preinjection values. erate hypoxic conditions, circulating catecholamines do not play a role in stimulating ventilation (14) . Because in our study the ICV injection of ANG IIs mimics the ventilatory responses to environmental hypoxia, i.e., a selective stimulatory action on VA (11), we suggest that the local brain RAS might be involved in the hyperventilatory response to environmental hypoxia in trout. In addition, the brain RAS may contribute to the increase in systemic vascular resistance and elevation of P DA generally observed in teleost fish exposed to hypoxia (11, 19) . ANG II is also a potent catecholamines secretagogue during periods of hypotension in trout, and ANG II and catecholamines act together to reestablish blood pressure (5) . The demonstration that ICV injection of ANG IIs and ANG III in trout elevates blood pressure supports the idea that the brain RAS might also be triggered during hypotensive stress. Whether this later effect may be mediated through a neural activation of the sympathetic nervous system remains to be delineated. (3) , suggesting that changes in the amino acid at positions 1 and 5 cause only minor effects with respect to the peripheral hypertensive action of the ANG II (29) . In addition, the lower hypertensive action of ANG III and the lack of effect of ANG IV are in line with the previous data in trout demonstrating that IA injection of human ANG III was less efficient than human ANG II for increasing P DA , and human ANG IV produced only a slight vasopressor response (39) . Collectively, these results in trout support the view that the NH 2 -terminal residue of the ANG II peptides plays a role in proper interaction with the putative cardiovascular angiotensin receptors in trout vascular tissue. Single IA injection of human ANG 1-7 provoked a slight, delayed, and long-lasting hypotensive response in trout (39) but without cardiovascular effect in the eel (6). We did not find any consistent cardiovascular action of ANG 1-7 in the present study suggesting that like in mammals, Asp 1 and Phe 8 of ANG II are important for full biological activity of the peptide.
Conclusion. This study demonstrates for the first time that after ICV injection of various ANG II peptides, only [Asp 1 ] and [Asn 1 ]-ANG II participate as potent neuroregulatory stimuli contributing to enhance ventilation in trout through stimulation of VA. In addition, ANG IIs, and to a lesser extent, ANG III, elevate both blood pressure and HR. ANG IV and ANG 1-7 were totally ineffective for changing the ventilatory or cardiovascular variables. Since [Asn 1 ]-ANG II and [Asp 1 ]-ANG II were detected in the trout brain tissue, our results suggest that these endogenous peptides may be implicated as neurotransmitters and/or neuromodulators in the regulation of cardioventilatory functions in trout. After peripheral injection, none of the ANG II peptides affect ventilation. Only two ANG IIs and ANG III, which were also detected in trout plasma, increased blood pressure without significantly decreasing HR, suggesting that these peptides may act as circulating hormones involved in cardiovascular regulation.
Perspectives and Significance
Although trout are aquatic gill-breathing fish and mammals are air lung-breathing animals, there are important similarities in the neuroanatomical networks and nervous mechanisms that control the ventilatory and cardiovascular systems between fish and mammals (47) . Furthermore, in fish as in mammals, ANG II, angiotensin binding sites, or angiotensin receptors are present within the same brain area involved in ventilatory and cardiovascular functions. The determination of the central ventilatory and cardiovascular actions of the angiotensin peptides in trout may thus provide new insights into the basic mechanisms that may operate in the central nervous system of higher vertebrates including humans to control cardioventilatory functions under hypoxic or hypotensive stress for example.
